Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

Tag Archives: trial

The Role of N-Acetylcysteine in Contrast Induced Nephro...
August 1, 2012 - Clinical

By: Neal Shah, Co-Editor-In-Chief – Contrast dyes enhance imaging for computer tomography (CT), magnetic resonance (MR), and X-rays.1  Dyes usually consist of barium, iodine, or gadolinium, depending on the procedure.2  CT and X-ray scans often use iodine for systemic imaging and barium sulfate for GI imaging, whereas MR imaging primarily uses gadolinium.2  Gadolinium and iodine…

Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics

By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug.   First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing…

Use of Donepezil in Patients with Delirium (but without...
July 1, 2012 - Clinical , Featured

By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Donepezil, brand name Aricept®, is an acetylcholinesterase inhibitor indicated as monotherapy for Alzheimer’s disease, the most common form of dementia.  Cholinergic deficiency in the cortex and basal forebrain contributes to cognitive deficits in these patients.  Donepezil reversibly, noncompetitively inhibits centrally active acetylcholinesterase, the enzyme responsible for…

The Challenges of Pediatric Clinical Drug Trials and Dr...
June 1, 2012 - Clinical , Featured , Professional Advice / Opinions

By: Shannon Tellier, Associate Student Editor – The disease burden in children outweighs the number of pediatric clinical drug trials currently being conducted.  The lack of data in pediatrics leads to drugs being used off-label and without sufficient knowledge of doses, tolerability, and efficacy.  In 1975, only 22% of products in the electronic Physicians’ Desk…

Transplantation in HIV +/- HBV/HCV Patients...
June 1, 2012 - Clinical , Featured

By: Jayoung Park, Pharm.D. Candidate c/o 2013 – Traditionally, human immunodeficiency virus (HIV)-infected patients have generally been excluded from organ transplantation.1  One of the principal concerns was that immunosuppression would accelerate HIV/acquired immune deficiency syndrome (AIDS), resulting in increased mortality and a “waste” of organs.1 A study entitled, “Opportunistic Infections and Neoplasms Following Liver and…

Role of Calcium Channel Blockers and Beta Blockers in C...
May 1, 2012 - Clinical , Featured

By: Lunbao Huang Pharm D. Candidate c/o 2013 – The seventh report of the Joint National Committee on high blood pressure (JNC-7) states that most classes of antihypertensive drugs such as angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers (BBs), diuretics, and aldosterone-receptor antagonists can be used for hypertensive heart failure patients except…

Student Pharmacist Star of the Month: Michelle Pernice...
April 1, 2012 - Professional Advice / Opinions

By: Marie Huang – Each month, the Rho Chi Post has the wonderful opportunity to sit down with an inspiring leader among the student pharmacists here at St. John’s University College of Pharmacy and Allied Health Professions – someone who is not afraid to stand apart from the crowd and can be the change he…

Sativex®: A Realistic Option for Advanced Cancer Pain?...
April 1, 2012 - Clinical , Featured , In the News / Politics

By: Kathlynn Ferrer, Pharm.D. Candidate c/o 2013 – Nabiximols (Sativex®) is a buccal spray that has been approved for use in the UK, Spain, Germany, Denmark, New Zealand, and Canada. The active ingredients in this product are Tetrahydrocannabinol and Cannabidiol, two kinds of cannabinoids1. Cannabinoids are chemical compounds that stimulate cannabinoid receptors and are the…

Korlym® For Endogenous Cushing’s Syndrome...
April 1, 2012 - Clinical , In the News / Politics

By: Alexandra Alleva, Pharm.D. Candidate c/o 2013 – On February 17, 2012, the US Food and Drug Administration (FDA) approved the first medication indicated specifically for patients with endogenous Cushing’s syndrome, a hormone disorder characterized by elevated blood levels of cortisol.  Mifepristone (Korlym®) is for the treatment of glucose intolerance and Type 2 Diabetes Mellitus…

HMG-CoA Reductase Inhibitors And Memory Loss...
April 1, 2012 - Clinical , Featured

By: Yufan (Frank) Liu, Pharm.D. Candidate c/o 2013 – Results of numerous epidemiological studies have indicated that having high serum cholesterol can lead to coronary heart disease (CHD). 1 More specifically having high LDL cholesterol puts patients at risk for angina and heart attack.2 To reduce this risk HMG-CoA reductase inhibitors, also known as statins,…

Brilinta® vs. Plavix® in Patients with Acute Coronary...
February 1, 2012 - Clinical , Featured

By: Ronik Saha, Pharm.D. Candidate c/o 2013 – Clopidogrel (Plavix®) is a thienopyridine antiplatelet agent, which exerts its antiplatelet effects via in vivo conversion to an active thiol metabolite that irreversibly blocks the P2Y-12 component of platelet ADP receptors.  This prevents activation of the GP2B/3A complex, thereby preventing platelet aggregation.  Along with aspirin, clopidogrel reduces…

Proton Pump Inhibitors and the Treatment of Osteoporosi...
February 1, 2012 - Clinical , Featured

By: Neal Shah – Osteoporosis is a disease of the bone characterized by decreased bone mineral density (BMD), which reduces the ability of bone to provide adequate structural support.  The main cause of this decreased BMD is inadequate calcium intake or absorption.  The decreased BMD can cause diffuse lesions throughout the skeletal system and can…

Bydureon®: A Weekly Injection for Type 2 Diabetes Mell...
February 1, 2012 - Clinical , Featured , In the News / Politics

By: Mohamed Dungersi – On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus (T2DM), as an adjunct to diet and exercise.  Bydureon®, a product of Amylin Pharmaceuticals, is a modified formulation of the twice-daily injection, Byetta® (exenatide).  It is the first once-a-week medication for T2DM in the market.…

Hope on the Horizon: Chikungunya Vaccine Trial Begins!...
January 1, 2012 - Clinical , Featured , In the News / Politics

By: Ebey P. Soman – Since its discovery in Tanganyika (modern day Mozambique and Tanzania in Africa) in 1952, Chikungunya virus outbreaks have been documented in Africa, South Asia, and Southeast Asia.  Due to recent globalization and increased travel, infection has also spread outside of tropical regions and even into western nations (such as the…

New Oral Direct Thrombin Inhibitors and Factor Xa Antic...
January 1, 2012 - Clinical , Featured , In the News / Politics

By: Neal Shah – Anticlotting agents are staples in the prevention and treatment of thrombotic disorders, such as deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction, and atrial fibrillation.1  Intravenous medications, such as unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct thrombin inhibitors (DTI), are commonly used in, both, inpatient and outpatient settings.…

FDA Approves Edarbyclor®...
January 1, 2012 - Clinical , In the News / Politics

By: Gokul Kalla, Pharm.D. Candidate c/o 2013 – Hypertension is a chronic disease that affects one out of every three Americans.  Leaving the condition untreated could increase the risk of serious health consequences such as a stroke or a heart attack.  On December 21, the FDA approved Takeda Pharmaceuticals’ Edarbyclor® (azilsartan medoxomil and chlorthalidone) for…

Clevidipine in the Management of Hypertensive Emergency...
January 1, 2012 - Clinical , Featured

By: Neal Shah – Defined by the Joint National Committee, hypertension (HTN) is a systolic blood pressure (SBP) greater than or equal to 140 mmHg and a diastolic blood pressure (DBP) greater than or equal to 90 mmHg.  Patients with Stage 1 HTN have a SBP between 140 and 159 mmHg and DBP between 90…

Xigris: A Worldwide Withdrawal...
January 1, 2012 - Clinical , In the News / Politics

By: Khilna Patel, Pharm.D. Candidate c/o 2012 – On October 25 of this year, Eli Lilly and Company announced a worldwide market withdrawal of Xigris (drotrecogin alfa), a drug previously indicated to treat severe sepsis in high-risk patients.  Drotrecogin alfa is a recombinant form of human activated protein C.  The efficacy of drotrecogin alfa was…

Differences Between Antagonists and Inverse Agonists...
December 1, 2011 - Clinical

By: Neal Shah – There are two major classifications of drug-receptor activity: agonism and antagonism. Agonism occurs when a molecule binds to a receptor, causes an exertion of normal receptor operation, and eventually causes a response. Antagonism of a receptor occurs when a molecule binds to the receptor and does not allow activity to occur.1…

Ivabradine: A Novel I(f) Blocker for Stable Angina...
December 1, 2011 - Clinical

By: Neal Shah – Part I:              Preface. Part II:             Brief review of cardiac electrophysiology. Part III:           Ivabradine as a novel If blocker for the use of stable angina. Part IV:           On the horizon: trimetazidine. – PREFACE When viewed anatomically, the heart may seem like a simple organ.  However, the electrophysiological aspects of the heart are…

Pharmacogenetic Applications in Clinical Practice...
November 1, 2011 - Clinical , Featured

By: Neal Shah – The focus of pharmacy is rapidly shifting from simple filling and dispensing of prescriptions to preventative medicine and efficient clinical practice. The field of genetics has been incorporated in many defining therapies and will continue to shape how we treat our patients. Examples discussed here are the roles of human leukocyte…

Faculty Spotlight: Dr. Parnali Chatterjee...
October 1, 2011 - Featured , Professional Advice / Opinions

By: Ebey P. Soman – Meet Dr. Parnali Chatterjee, a new faculty member in our St. John’s University family. I had the opportunity to meet Dr. Chatterjee at the doctoral seminar hosted by Dr. Lin Mantell entitled, “Drug Metabolism and Pharmacokinetics in Drug Discovery and Development.” I was introduced to Dr. Chatterjee through Dr. Frank…

Post navigation

Newer posts →


Do You Want to be a Published Author? Submit your Article(s) Today!



Tweets by @RhoChiPost

HOME: Home Page

VOLUMES / ISSUES: 14 . 13 . 12 . 11 . 10 . 9 . 8 . 7 . 6 . 5 . 4 . 3 . 2 . 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List


Copyright © 2011-2025 Rho Chi Post